Log In
Print
BCIQ
Print
Print this Print this
 

KB001-A

  Manage Alerts
Collapse Summary General Information
Company KaloBios Pharmaceuticals Inc.
DescriptionHumanized antibody fragment against PcrV (V-antigen) on Pseudomonas aeruginosa
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I/II
Standard IndicationPneumonia
Indication DetailsPrevent ventilator-associated pneumonia (VAP) caused by P. aeruginosa
Regulatory Designation

U.S. - Fast Track (Prevent ventilator-associated pneumonia (VAP) caused by P. aeruginosa)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today